Lee Dongin, Lee Wookjae, Kim Hwang-Phill, Kim Myong, Ahn Hyun Kyu, Bang Duhee, Kim Kwang Hyun
Department of Chemistry, Yonsei University, Seoul 03722, Republic of Korea.
IMBdx, Seoul 08506, Republic of Korea.
Cancers (Basel). 2023 May 22;15(10):2868. doi: 10.3390/cancers15102868.
Patients with hematuria are commonly given an invasive cystoscopy test to detect bladder cancer (BC). To avoid the risks associated with cystoscopy, several urine-based methods for BC detection have been developed, the most prominent of which is the deep sequencing of urine DNA. However, the current methods for urine-based BC detection have significant levels of false-positive signals. In this study, we report on uAL100, a method to precisely detect BC tumor DNA in the urine without tumor samples. Using urine samples from 43 patients with BC and 21 healthy donors, uAL100 detected BC with 83.7% sensitivity and 100% specificity. The mutations identified in the urine DNA by uAL100 for BC detection were highly associated with BC tumorigenesis and progression. We suggest that uAL100 has improved accuracy compared to other urine-based methods for early BC detection and can reduce unnecessary cystoscopy tests for patients with hematuria.
血尿患者通常会接受侵入性膀胱镜检查以检测膀胱癌(BC)。为避免与膀胱镜检查相关的风险,已开发出几种基于尿液的膀胱癌检测方法,其中最突出的是尿液DNA深度测序。然而,目前基于尿液的膀胱癌检测方法存在显著水平的假阳性信号。在本研究中,我们报告了uAL100,一种无需肿瘤样本即可精确检测尿液中膀胱癌肿瘤DNA的方法。使用来自43例膀胱癌患者和21名健康供体的尿液样本,uAL100检测膀胱癌的灵敏度为83.7%,特异性为100%。uAL100在尿液DNA中鉴定出的用于膀胱癌检测的突变与膀胱癌的发生和进展高度相关。我们认为,与其他基于尿液的早期膀胱癌检测方法相比,uAL100具有更高的准确性,并且可以减少血尿患者不必要的膀胱镜检查。